Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 26, 2023; 11(27): 6543-6550
Published online Sep 26, 2023. doi: 10.12998/wjcc.v11.i27.6543
Amniotic membrane mesenchymal stromal cell-derived secretome in the treatment of acute ischemic stroke: A case report
Fu-Hong Lin, Yu-Xiao Yang, Yu-Jun Wang, Suresh Kumar Subbiah, Xiao-Yun Wu
Fu-Hong Lin, Department of Neurology, Affiliated Hospital of Chifeng College, Chifeng 024000, Inner Mongolia Autonomous Region, China
Yu-Xiao Yang, Yu-Jun Wang, Xiao-Yun Wu, Department of Technology, Beijing Protercell Biotechnology Co. Ltd., Beijing 102600, China
Yu-Xiao Yang, Yu-Jun Wang, Xiao-Yun Wu, Department of Technology, Inner Mongolia Protercell Biotechnology Co. Ltd., Hohhot 010000, Inner Mongolia Autonomous Region, China
Suresh Kumar Subbiah, Centre for Materials Engineering and Regenerative Medicine, Bharath Institute of Higher Education and Research, Chennai 600126, India
Xiao-Yun Wu, Department of Interventional, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, China
Author contributions: Lin FH and Wang YJ contributed to conception and design, financial support, collection and/or assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript; Subbiah SK and Yang YX contributed to provision of study material, collection and/or assembly of data, data analysis, interpretation, and final approval of manuscript; Wu XY contributed to conception and design, manuscript writing, data analysis, interpretation, and final approval of manuscript.
Supported by the National Natural Science Foundation of China, No. 81960252 and No. 81860157; Natural Science Foundation of Inner Mongolia, No. 2021LHMS08019 and No. 2021LHMS08023.
Informed consent statement: The patient involved in this study gave her written informed consent authorizing disclosure of protected health information.
Conflict-of-interest statement: All authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Yun Wu, PhD, Professor, Department of Technology, Research Center for Hua-Da Precision Medicine of Inner Mongolia Autonomous Region, No. 69 Horqin South Road, Hohhot Economic and Technological Development Zone, Hohhot, Hohhot 010000, Inner Mongolia Autonomous Region, China. stemcells@foxmail.com
Received: June 1, 2023
Peer-review started: June 1, 2023
First decision: July 17, 2023
Revised: July 30, 2023
Accepted: August 18, 2023
Article in press: August 18, 2023
Published online: September 26, 2023
Processing time: 111 Days and 2.3 Hours
Abstract
BACKGROUND

Stroke is the second and third leading cause of death and disability, respectively. To date, no definitive treatment can repair lost brain function. Recently, various preclinical studies have been reported on mesenchymal stromal cells (MSCs) and their derivatives and their potential as alternative therapies for stroke.

CASE SUMMARY

A 45-year-old female suffered an acute stroke, which led to paralysis in the left upper and lower limbs. The amniotic membrane MSC-derived secretome (MSC-secretome) was intravenously transplanted once a week for 4 wk. MSC-secretome-regulated regulatory T cells were investigated for the beneficial effects. The clinical improvement of this patient was accompanied by an increased frequency of regulatory T cells after transplantation.

CONCLUSION

Intravenous administration of MSC-secretome can potentially treat patients who suffer from acute ischemic stroke.

Keywords: Acute stroke; Amniotic membrane; Mesenchymal stromal cells; Extracellular vesicle; Clinical trial; Case report

Core Tip: Mesenchymal stromal cells (MSCs) and their derivatives have been studied as a therapeutic alternative for stroke. A 45-year-old female suffered an acute stroke, causing paralysis in the left upper and lower limbs. We transplanted the amniotic membrane MSC-derived secretome once a week for 4 wk. The clinical improvement of this patient was accompanied by an increased frequency of regulatory T cells after transplantation. This study demonstrated that intravenous transplantation of the MSC-secretome can potentially treat patients who suffer from acute ischemic stroke.